BioCycive, a biotechnology company focused on pharmaceutical research, has selected Nova Scotia as the location for its company headquarters for research & development. Shalabh Gupta, MD, MPA, BioCycive’s CEO has declared Halifax an ideal setting for his business based on the academic resources, teaching hospitals and access to a range of patients with varying health issues.
BioCycive was first introduced to the market through research colleagues and NSBI trade missions that connected Dr. Gupta with key stakeholders. The NSBI team also facilitated introductions to university life science faculties, ACOA, BioNova and other key players in the province to provide an in-depth orientation of the province’s capabilities to support a new company of this nature.
BioCycive’s core strategy is to in-license small molecule drugs, which can be advanced to clinical trials within 2-3 years, and have shown some proof of activity in animal models. BioCycive team is made up of former biopharma executives who were responsible for in-licensing drugs for global pharmaceutical companies. With that background and understanding, the company prides itself in being able to identify targets, mechanisms of action and drug molecules that have a very high likelihood of being relevant and interesting to large pharmaceutical companies.
BioCycive’s core team then works with vendors, strategic partners and CROs globally to get these drugs into clinic as efficiently and as quickly as possible.
Dr. Gupta states, “We selected Nova Scotia to establish our company based on the sophisticated academic and research resources here. This region is truly unique in its life sciences advancements as a small, manageable market and we look forward to growing our business in partnership with our colleagues across the sector.”
“We are pleased to welcome BioCycive as the newest member of our life sciences sector,” said Ron Smith, Interim CEO of Nova Scotia Business Inc. “BioCycive’s decision to choose Nova Scotia as their first Canadian location is a testament, not only to the caliber of our infrastructure, but to the collaborative approach we take with our partners in industry and academia, when attracting new investment to the province.”
BioCycive is a privately held biopharmaceutical research company dedicated to developing molecules to augment the existing menu of available therapies for oncology and infectious diseases.
Started by Dr. Shalabh Gupta in late 2010, the company operates with a team of key personnel, scientific advisors and strategic advisors who bring a wealth of experience in academic research, business operations and finance. BioCycive has roots in Silicon Valley and utilizes a global network of strategic partners, vendors and consultants to advance its drug development programs.
BioCycive selectively researches and targets drug candidates that can be advanced to the next stage of development. BioCycive’s work with these drug candidates includes PD, PK, toxicology modifications and testing in appropriate animal models, which reduces the risks to potential buyers or partners.
Drawing on backgrounds in research science, clinical medicine, Wall Street finance and business management, BioCycive seeks to take a new approach to drug management.
For more information or to request an interview, please contact:
NATIONAL Public Relations